Roche Secures Patent License for Obesity Drug CT-996 in $100 Million Deal with Structure Therapeutics
核心洞察
Roche has entered into a patent licensing agreement with Structure Therapeutics subsidiary Gasherbrum Bio (搜索) to secure rights for its investigational obesity (搜索) pill CT-996, paying $100 million upfront plus low-single-digit royalties on net sales.
The December 30, 2025 agreement grants Roche non-exclusive rights to manufacture, use, and sell products containing CT-996 while addressing potential patent infringement concerns identified through IP landscape analysis.
Analysts view the deal as validation of Structure's intellectual property portfolio in GLP-1 receptor (搜索) agonist small molecules, though it represents incremental rather than transformational value for the biotech.
Roche has secured patent rights for its investigational obesity (搜索) drug CT-996 through a $100 million licensing agreement with Structure Therapeutics, addressing potential intellectual property concerns that could have complicated the drug's development path.
The agreement, executed on December 30, 2025, and disclosed in an SEC filing on Monday, grants Roche's subsidiary Genentech non-exclusive rights to "make, use, sell, offer for sale and import" products containing CT-996. In return, Roche will pay Structure's subsidiary Gasherbrum Bio (搜索) $100 million upfront plus royalties in the low-single-digit range on net sales.
Patent Concerns Drive Licensing Deal
According to Leerink Partners analysts, "Roche approached [Structure] for the license after a full analysis of the IP landscape and a need for a license to avoid any potential infringement." The deal appears designed to clear legal uncertainties surrounding CT-996's composition that could have impacted future development and commercialization efforts.
Structure Therapeutics noted that the licensed patents relate specifically to the CT-996 scaffold and "does not encumber any of the Company's ongoing programs, including aleniglipron (搜索)," Structure's own GLP-1 agonist currently in development. The agreement also includes "a covenant not to assert certain potential future patents" related to Genentech's manufacturing and commercialization of its products.
Market Response and Strategic Implications
BMO Capital Markets analysts characterized the agreement as "a mild positive" for Structure, noting it "highlights the strength of Structure's IP protections but represents a muted read-through to the stock." Structure's shares rose 1.96% in after-hours trading to $64, up from a closing price of $62.77.
However, BMO emphasized that "for Structure, Monday's agreement with Roche is not the large Pharma partnership that some Structure owners have been anxiously awaiting." The biotech has been seeking major partnerships following promising Phase IIb data for aleniglipron (搜索), which demonstrated an 11.3% placebo-adjusted reduction in weight at 36 weeks.
William Blair analysts previously noted these findings are competitive with Eli Lilly's obesity (搜索) pill orforglipron, with Structure's stock spiking 100% following the data release, potentially driven by expectations of Big Pharma deals.
Strengthening Roche's Obesity Portfolio
The patent licensing agreement represents another strategic move in Roche's aggressive expansion into the obesity (搜索) market. In late 2023, the pharmaceutical giant acquired Carmot Therapeutics (搜索) for $2.7 billion, bringing CT-996 and the dual GLP-1 and GIP receptor (搜索) agonist CT-388 into its portfolio. This was followed by a $5.3 billion partnership with Zealand Pharma in May 2024 to co-develop the amylin analog petrelintide.
Leerink Partners viewed the deal as supporting "Structure management's view that the company has the broadest and strongest global IP portfolio related to GLP-1 receptor (搜索) agonist small molecules." BMO analysts added that "Structure now appears an even more viable option for large Pharma to partner with and expand commercially in the future."
Looking Forward
While the licensing agreement provides Structure with "some incremental cash and future revenue," according to BMO analysts, it falls short of the transformational partnership many investors had anticipated. The deal does, however, validate Structure's intellectual property position in the competitive oral obesity (搜索) treatment landscape and removes potential legal obstacles for Roche's CT-996 development program.